Malignancies, comparison between different bDMARDs/tsDMARDs (observational studies)
| Study ID | Registry | Intervention | Control | aHR (i vs C) | Risk of bias |
| All types of cancer | |||||
| De Germay et al 48 2020 | Pharmacov. database | ABA | Other bDMARD | 0.98 (0.91; 1.05) | High |
| Kim et al 49 2019 | Claims dataset | TCZ | TNFi | 0.98 (0.80; 1.19) | High |
| Montastruc et al 52 2019 | Claims dataset | ABA | Other bDMARD | 1.17 (1.06; 1.30) | High |
| Ozen et al 73 2019 | FORWARD | ABA | Other bDMARD | 1.89 (0.93; 3.84) | Unclear |
| Kremer et al 71 2021 | CORRONA | TOFA | bDMARD | 1.04 (0.68; 1.61) | Low |
| Simon et al 74 2019 | Claims dataset | ABA | other bDMARD | 1.09 (1.02; 1.16) | High |
| Non-melanoma skin cancer | |||||
| Kremer et al 71 2021 | CORRONA | TOFA | bDMARD | 1.02 (0.69; 1.50) | Low |
| Montastruc et al 52 2019 | Claims dataset | ABA | Other bDMARD | 1.45 (1.03; 1.39) | High |
| Ozen et al 73 2019 | FORWARD | ABA | Other bDMARD | 1.10 (0.57; 2.11) | Unclear |
| Melanoma | |||||
| De Germay et al 48 2020 | Pharmacov. database | ABA | Other bDMARD | 1.56 (1.17; 2.08) | High |
| Kim et al 49 2019 | Claims dataset | TCZ | TNFi | 0.71 (0.36; 1.40) | High |
| Montastruc et al 52 2019 | Claims dataset | ABA | Other bDMARD | 0.86 (0.38; 1.59) | High |
| Lymphoma | |||||
| De Germay et al 48 2020 | Pharmacov. database | ABA | Other bDMARD | 0.76 (0.60; 0.97) | High |
| Hellgren et al 53 2021 | SRQ | ADA | ETA | 1.02 (0.52; 1.99) | Low |
| INF | 0.64 (0.27; 1.56) | ||||
| CZP | <5 lymphomas | ||||
| GOL | <5 lymphomas | ||||
| ABA | 1.61 (0.50; 5.22) | ||||
| RTX | <5 lymphomas | ||||
| TCZ | <5 lymphomas | ||||
| ANA | <5 lymphomas | ||||
| Kim et al 49 2019 | Claims dataset | TCZ | TNFi | 1.31 (0.60; 2.88) | High |
| Simon et al 74 2019 | Claims dataset | ABA | Other bDMARD | 1.27 (0.94; 1.72) | High |
Values in bold highlight statistically significant effect sizes. Additional details in online supplemental tables S44-S67).
ABA, abatacept; ADA, adalimumab; aHR, adjusted HR; ANA, anakinra; bDMARD, biological disease-modifying antirheumatic drug; c, control; CORRONA, Consortium of Rheumatology Researchers of North America; CZP, certolizumab pegol; ETA, etanercept; FORWARD, National Databank for Rheumatic Diseases longitudinal prospective observational study; GOL, golimumab; i, intervention; INF, infliximab; Pharmacov, pharmacovigilance; RTX, rituximab; SRQ, Swedish Rheumatology Quality Register; TCZ, tocilizumab; TNFi, TNF inhibitor; TOFA, tofacitinib; tsDMARD, targeted synthetic DMARD.